Correlation Between Emergent Biosolutions and Aquestive Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Emergent Biosolutions and Aquestive Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Emergent Biosolutions and Aquestive Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Emergent Biosolutions and Aquestive Therapeutics, you can compare the effects of market volatilities on Emergent Biosolutions and Aquestive Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Emergent Biosolutions with a short position of Aquestive Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Emergent Biosolutions and Aquestive Therapeutics.

Diversification Opportunities for Emergent Biosolutions and Aquestive Therapeutics

0.4
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Emergent and Aquestive is 0.4. Overlapping area represents the amount of risk that can be diversified away by holding Emergent Biosolutions and Aquestive Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aquestive Therapeutics and Emergent Biosolutions is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Emergent Biosolutions are associated (or correlated) with Aquestive Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aquestive Therapeutics has no effect on the direction of Emergent Biosolutions i.e., Emergent Biosolutions and Aquestive Therapeutics go up and down completely randomly.

Pair Corralation between Emergent Biosolutions and Aquestive Therapeutics

Considering the 90-day investment horizon Emergent Biosolutions is expected to under-perform the Aquestive Therapeutics. In addition to that, Emergent Biosolutions is 1.04 times more volatile than Aquestive Therapeutics. It trades about -0.23 of its total potential returns per unit of risk. Aquestive Therapeutics is currently generating about -0.04 per unit of volatility. If you would invest  352.00  in Aquestive Therapeutics on December 30, 2024 and sell it today you would lose (50.00) from holding Aquestive Therapeutics or give up 14.2% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Emergent Biosolutions  vs.  Aquestive Therapeutics

 Performance 
       Timeline  
Emergent Biosolutions 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Emergent Biosolutions has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Aquestive Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Aquestive Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest conflicting performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Emergent Biosolutions and Aquestive Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Emergent Biosolutions and Aquestive Therapeutics

The main advantage of trading using opposite Emergent Biosolutions and Aquestive Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Emergent Biosolutions position performs unexpectedly, Aquestive Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aquestive Therapeutics will offset losses from the drop in Aquestive Therapeutics' long position.
The idea behind Emergent Biosolutions and Aquestive Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Complementary Tools

Money Managers
Screen money managers from public funds and ETFs managed around the world
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance